Compare UTZ & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | REPL |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | 465 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2018 | 2018 |
| Metric | UTZ | REPL |
|---|---|---|
| Price | $14.24 | $13.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $11.93 | $5.67 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-21-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,438,800,000.00 | N/A |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $1.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $6.78 | $1.50 |
| 52 Week High | $14.33 | $16.33 |
| Indicator | UTZ | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 71.28 | 47.37 |
| Support Level | $14.18 | $12.40 |
| Resistance Level | $14.27 | $16.02 |
| Average True Range (ATR) | 0.04 | 0.72 |
| MACD | -0.09 | -0.28 |
| Stochastic Oscillator | 43.33 | 24.12 |
Utz Brands Inc is a manufacturer of branded salty snacks based in the United States. It produces various salty snack foods, including potato chips, tortilla chips, pretzels, cheese snacks, party mixes, pork skins, ready-to-eat popcorn, and other snacks, which include salsa and dips. These products are offered through its flagship brands like Utz, On The Border, Zapp's, and Boulder Canyon, along with other brands, including Golden Flake, Miguelito's, Hawaiian, Bachman, Tim's Cascade, Dirty Potato Chips, TGI Fridays, and Vitner's. The company's products are packaged in a variety of different sizes and configurations, ranging from individual packages to shareable bulk containers. It also sells certain third-party branded products through its distribution network.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.